ClinicalTrials.gg
RecruitingNCT05579132Updated Oct 30, 2026

A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)

A Phase 1/2 interventional study of MK-1045 in Acute Lymphoblastic Leukemia, sponsored by MSD R&D (China) Co., Ltd.. Recruiting at 11 sites in China. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by MSD R&D (China) Co., Ltd. (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2022; still recruiting 4 years later.
Updated Oct 30, 2026Eligibility revisedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
203
Allocation
Non-randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 232 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in China — 113 open to participants now, 125 under way, 11 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · China.

Planned enrollment
21st of 209
203 · median 45
Started
2022
with 27 others
Phase 1/2
33 of 232
14 open now
Primary completion
2028-12
later than 105 of 124 live
Registered
126th of 232
by date

Among the 232 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in China, this one is the 21st largest by planned enrollment of the 209 interventional ones that give a count, is one of 28 that started in 2022, is one of 33 in phase 1/2, reaches primary completion later than 105 of the 124 other live ones, and was the 126th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 475 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

113 of the 232 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in China are open now. Recruiting first, the newest first:

108 more — sign in →

All 113 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 372 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 259 (70%) stop at 75 or younger; 248 take children under 18; 29 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in China, or all of them as a file.
02

Study summary

Researchers are looking for new ways to treat people with a type of blood cancer called precursor B-cell Acute Lymphoblastic Leukemia (B-ALL) that is relapsed- the cancer has come back after treatment, or refractory - the current treatment has stopped working to slow or stop cancer growth. This study will have two parts. In the first part (dose escalation phase) the goal is to learn about the safety of a study treatment, MK-1045, and to find the best dose level of MK-1045 that is tolerated and may work to treat B-ALL. In the second part (Phase II) researchers want to learn how well MK-1045 works to treat B-ALL.

03

Conditions studied

  • Acute Lymphoblastic Leukemia
04

Who can participate

The criteria were revised on the registry on Oct 30, 2026. See what changed

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

The main inclusion criteria include but are not limited to:

  • Adult participants must be age 18 or older
  • Pediatric participants must be at least 2 years old and less than 18 years old.
  • Diagnosis of precursor B-cell acute lymphoblastic leukemia (B-ALL) and have more than 5% blasts in the bone marrow by morphological assessment
  • Participants with Ph-negative B-ALL with any of the following /relapse criteria:

    • Failure to achieve complete remission after initial induction therapy;
    • Failure to achieve complete remission after salvage treatment;
    • Relapse with first remission duration ≤12 months
    • Second or later relapse
    • Relapse after HSCT
  • Participants with Ph-positive B-ALL who have received 2 (or more) tyrosine kinase inhibitors (TKIs) and meet the refractory/relapse criteria above or, those with the T315I mutation

The main exclusion criteria include but are not limited to:

  • History of Burkitt's leukemia.
  • Received anti-CD19 therapy within 3 months prior to entering the study
  • Received allogeneic HSCT within 12 weeks prior to entering the study
  • Received prior treatment with chimeric antigen receptor T cell (CAR-T) within 3 months prior to entering the study
  • History or presence of central nervous system (CNS) pathology
  • Has CNS infiltration. Participants who had previous CNS infiltration, but it was controlled with intrathecal therapy are permitted to enroll.
  • History of immunodeficiency, including history of any positive test result for (HIV) antibody.
  • History of serious cardiovascular and cerebrovascular disease
  • Has active diseases that may relapse
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
203 participants (estimated)

Study arms

  • Experimental
    MK-1045: Dose Escalation Phase- Adult Cohort

    Adults in the dose escalation phase will receive a target dose level of MK-1045 from 600 μg to 120,000 μg, administered by intravenous (IV) infusion. MK-1045 will be administered once per week, in treatment cycles defined as 4 weeks of MK-1045 treatment.

    Drug: MK-1045

  • Experimental
    MK-1045 : Dose Escalation Phase- Pediatric Cohort

    Pediatric participants will receive a target dose level of MK-1045 from 320 μg to 60000 μg, with dosing further based upon weight. MK-1045 will be administered by IV infusion once per week, in treatment cycles defined as 4 weeks of MK-1045 treatment.

    Drug: MK-1045

Interventions

  • MK-1045 is administered by IV infusion once a week (QW), 4 weeks per treatment cycle, starting with 2 cycles of induction treatment. After a 2-week treatment-free interval, responders to induction treatment receive 3 cycles of consolidation therapy, and up to 7 cycles of maintenance treatment or until intolerable toxicity, disease progression, withdrawal of informed consent, loss to follow-up, receipt of other antitumor therapy, or death, whichever occurs first. Following each consolidation and maintenance cycle, there are treatment-free intervals ranging 2-8 weeks.

    Also known as: CN201

06

What researchers measure

Primary outcomes

  1. Dose Escalation Phase: Number of Participants who Experience at Least One Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 24 months

  2. Dose Escalation Phase: Number of Participants who Discontinue Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 21 months

  3. Dose Escalation Phase: Number of Participants Who Experience a Dose-limiting Toxicity (DLT)

    A DLT is defined as any of the following toxicities and judged by the investigator to be related to the study drug: Hematologic toxic reactions: Due to the influence of the primary disease (leukemia), thrombocytopenia, leukopenia, and anemia are not considered as DLTs. Non-Hematologic toxic reactions: Grade 4 non-hematologic toxicity that does not recover to ≤ Grade 2 within 14 days of best supportive therapy. Grade 3 rash, fatigue, fever, or infection will not be classified as DLT; other Grade 3 non-hematologic toxicities that do not recover to ≤ Grade 2 within 14 days of best supportive therapy is considered DLTs. Others that are considered as DLTs: Other toxicities considered by the investigator that result in permanent drug withdrawal.

    Time frame: Up to 28 days

  4. Dose Escalation Phase: Maximum Tolerated Dose (MTD) of MK-1045

    The MTD will be determined based on the incidence of DLT in each dose level. The dose level for which the DLT rate is closest to the target DLT rate (30%) will be selected as the MTD.

    Time frame: Up to approximately 21 months

  5. Phase II: Complete Remission (CR) Rate

    Complete remission is defined as follows: \< 5% blasts in the bone marrow, no circulating lymphoblasts or extramedullary disease, and full recovery of peripheral blood counts: Platelets ≥100×10\^9/L, and absolute neutrophil count (ANC) ≥1.0×10\^9/L. The number of participants with CR will be presented.

    Time frame: Up to approximately 10 weeks

Secondary outcomes

  1. Dose Escalation Phase: Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of MK-1045

    Blood samples will be collected to determine the AUC from time 0 to the last concentration that can be accurately measured of MK-1045

    Time frame: At designated time points up to approximately 24 weeks

  2. Dose Escalation Phase: Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of MK-1045

    Blood samples will be collected to determine the AUC0-inf of MK-1045.

    Time frame: At designated time points up to approximately 24 weeks

  3. Dose Escalation Phase: Area Under the Concentration-time Curve From Time 0 to 168 hours (AUC0-168)

    Blood samples will be collected to determine the AUC from time to 168 hours after the start of infusion of MK-1045

    Time frame: At designated time points up to approximately 24 weeks

  4. Dose Escalation Phase: AUC From Time 0 to 168 Hours at Steady State (AUC0-tau)

    Blood samples will be collected to determine the AUC0 -tau

    Time frame: At designated time points up to 24 weeks

  5. Dose Escalation Phase: Maximum Serum Drug Concentration (Cmax) of MK-1045

    Blood samples will be collected to determine the maximum serum drug concentration, obtained directly from the measured value of the plasma concentration-time curve

    Time frame: At designated time points up to approximately 32 weeks

  6. Dose Escalation Phase: Time to Maximum Serum Drug Concentration of MK-1045

    Blood samples will be collected to determine the Tmax of MK-1045

    Time frame: At designated time points up to approximately 24 weeks

  7. Dose Escalation Phase: Concentration at End of Dosing Interval (Ctrough) of MK-1045

    Blood samples will be collected to determine the Ctrough of MK-1045

    Time frame: At designated time points up to approximately 12 months

  8. Dose Escalation Phase: Apparent Terminal Half Life (t1/2)

    Blood samples will be collected to determine the t1/2 of MK-1045

    Time frame: At designated time points up to approximately 24 weeks

  9. Dose Escalation Phase: Apparent Clearance (CL) of MK-1045

    Blood samples will be collected to determine the CL of MK-1045

    Time frame: At designated time points up to approximately 24 weeks

  10. Dose Escalation Phase: Apparent Volume of Distribution (Vz) of MK-1045

    Blood samples will be collected to determine the Vz of MK-1045

    Time frame: At designated time points up to approximately 24 weeks

  11. Dose Escalation Phase: Apparent Volume of Distribution at Theoretical Steady State (Vss) of MK-1045

    Blood samples will be collected to determine the Vss of MK-1045

    Time frame: At designated time points up to approximately 24 weeks

  12. Dose Escalation Phase: Mean Residence Time (MRT) of MK-1045

    Blood samples will be collected to determine the MRT of MK-1045

    Time frame: At designated time points up to approximately 24 weeks

  13. Dose Escalation Phase: Peripheral B Cell Depletion of MK-1045

    B cell depletion will be determined at each timepoint by comparing absolute B cell numbers (as determined by flow cytometry) with those at baseline

    Time frame: Baseline and at designated time points up to approximately 12 months

  14. Dose Escalation Phase: Peripheral Circulating T Cell Activation of of MK-1045

    Peripheral circulating T cell activation will be determined at each timepoint by comparing absolute T cell numbers and T cell activation markers with those at baseline

    Time frame: Baseline and at designated time points up to approximately 12 months

  15. Dose Escalation Phase: Percentage of Participants with Antidrug Antibodies (ADA) to MK-1045

    Blood samples collected at designated timepoints will be used to determine the percentage of participants who develop detectable ADAs to MK-1045

    Time frame: At designated time points up to approximately 12 months

  16. Dose Escalation Phase: Rate of Complete Remission (CR) and Complete Remission with Partial Hematologic Recovery (CRh)

    Complete remission is defined as follows: \< 5% blasts in the bone marrow, no circulating lymphoblasts or extramedullary disease, and full recovery of peripheral blood counts: Platelets ≥100×10\^9/L, and absolute neutrophil count (ANC) ≥1.0×10\^9/L. CRh is defined as meeting all of the following criteria: Satisfaction of all criteria for CR except partial recovery of peripheral blood counts (platelets ≥ 50 ×10\^9/L and ANC ≥ 0.5×10\^9/L). The percentage of participants with CR or CRh will be presented.

    Time frame: Up to approximately 10 weeks

  17. Dose Escalation Phase: Rate of CR, CRh, and Complete Response with Incomplete Hematologic Recovery (CRi)

    Complete remission is defined as follows: \< 5% blasts in the bone marrow, no circulating lymphoblasts or extramedullary disease, and full recovery of peripheral blood counts: Platelets ≥100×10\^9/L, and absolute neutrophil count (ANC) ≥1.0×10\^9/L. CRh is defined as meeting all of the following criteria: Satisfaction of all criteria for CR except partial recovery of peripheral blood counts (platelets ≥ 50 ×10\^9/L and ANC ≥ 0.5×10\^9/L). CRi is defined as follows: \<5% blasts in the bone marrow, No circulating lymphoblasts or extramedullary disease, and platelets \<100×10\^9/L and neutrophils ≥1.0×109/L or platelets ≥100 ×109/L and neutrophils \<1.0×10\^9/L. The percentage of participants with CR, CRh or CRi will be presented.

    Time frame: Up to approximately 10 weeks

  18. Dose Escalation Phase: Rate of Minimum Residual Disease (MRD)-negative Complete Remission

    MRD-negative is defined as less than 0.01% of leukemic cells were detected in bone marrow with a detection sensitivity no less than 10\^-4.

    Time frame: Up to approximately 12 months

  19. Dose Escalation Phase: Rate of Red Blood Cell and Platelet Transfusion Independence (TI)

    TI is defined as no transfusion for a period of at least 1 week (7 days). The percentage of participants having TI will be presented.

    Time frame: Up to approximately 24 months

  20. Phase II: Number of Participants Who Experience at Least 1 AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 24 months

  21. Phase II: Number of Participants who Discontinue Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 24 months

  22. Phase II: Maximum Serum Drug Concentration (Cmax) of MK-1045

    Blood samples will be collected to determine the maximum serum drug concentration, obtained directly from the measured value of the plasma concentration-time curve

    Time frame: At designated time points up to 4 weeks

  23. Phase II: Concentration at End of Dosing Interval (Ctrough) of MK-1045

    Blood samples will be collected to determine the Ctrough of MK-1045

    Time frame: At designated time points up to 4 weeks

  24. Phase II: Peripheral B Cell Depletion of MK-1045

    B cell depletion will be determined at each timepoint by comparing absolute B cell numbers (as determined by flow cytometry) with those at baseline

    Time frame: Baseline and at designated time points up to 4 weeks

  25. Phase II: Peripheral Circulating T Cell Activation of of MK-1045

    Peripheral circulating T cell activation will be determined at each timepoint by comparing absolute T cell numbers and T cell activation markers with those at baseline

    Time frame: Baseline and at designated time points up to 4 weeks

  26. Phase II: Concentration of Peripheral Cytokines

    Blood samples will be collected to compare peripheral blood cytokine levels at various time points with those at baseline

    Time frame: Baseline and at designated time points up to 4 weeks

  27. Phase II: Percentage of participants with Antidrug Antibodies (ADA) to MK-1045

    Blood samples collected at designated timepoints will be used to determine the percentage of participants who develop detectable ADAs to MK-1045

    Time frame: At designated time points up to 4 weeks

  28. Phase II: Rate of CR and CRh

    Complete remission is defined as follows: \< 5% blasts in the bone marrow, no circulating lymphoblasts or extramedullary disease, and full recovery of peripheral blood counts: Platelets ≥100×10\^9/L, and absolute neutrophil count (ANC) ≥1.0×10\^9/L. CRh is defined as meeting all of the following criteria: Satisfaction of all criteria for CR except partial recovery of peripheral blood counts (platelets ≥ 50 ×10\^9/L and ANC ≥ 0.5×10\^9/L). The percentage of participants with CR or CRh will be presented.

    Time frame: Up to approximately 10 weeks

  29. Phase II: Rate of CR/CRh/CRi

    CR is defined as follows: \< 5% blasts in the bone marrow, no circulating lymphoblasts or extramedullary disease, and full recovery of peripheral blood counts: Platelets ≥100×10\^9/L, and absolute neutrophil count (ANC) ≥1.0×10\^9/L. CRh is defined as meeting all of the following criteria: Satisfaction of all criteria for CR except partial recovery of peripheral blood counts (platelets ≥ 50 ×10\^9/L and ANC ≥ 0.5×10\^9/L). CRi is defined as follows: \<5% blasts in the bone marrow, No circulating lymphoblasts or extramedullary disease, and platelets \<100×10\^9/L and neutrophils ≥1.0×109/L or platelets ≥100 ×109/L and neutrophils \<1.0×10\^9/L. The percentage of participants with CR, CRh or CRi will be presented.

    Time frame: Up to approximately 10 weeks

  30. Phase II: Rate of Minimum Residual Disease (MRD)-negative Complete Remission

    MRD-negative is defined as less than 0.01% of leukemic cells were detected in bone marrow with a detection sensitivity no less than 10\^-4.

    Time frame: Up to approximately 24 months

  31. Phase II: Rate of Red Blood Cell and Platelet TI

    Red Blood Cell and Platelet TI is defined as no transfusion for a period of at least 1 week (7 days). The percentage of participants having TI will be presented.

    Time frame: Up to approximately 24 months

  32. Phase II: Proportion of Participants Undergoing Hematopoietic Stem Cell Transplantation (HSCT)

    The number of participants who undergo a HSCT during study participation will be presented.

    Time frame: Up to approximately 24 months

  33. Phase II: Duration of CR

    For participants who demonstrate a CR (defined as \< 5% blasts in the bone marrow, no circulating lymphoblasts or extramedullary disease, and full recovery of peripheral blood counts: Platelets ≥100×10\^9/L, and absolute neutrophil count (ANC) ≥1.0×10\^9/L) , duration of CR is defined as the time from the first documentation of a disease response of CR to the date of the first documented relapse event, or death due to any cause, whichever occurs first

    Time frame: Up to approximately 24 months

  34. Phase II: Duration of CR/CRh

    Duration of CR/CRh is defined as the time from the first documentation of a disease response of CR/CRh to the date of the first documented relapse event, or death due to any cause, whichever occurs first. Only participants who demonstrate a CR (defined as \< 5% blasts in the bone marrow, no circulating lymphoblasts or extramedullary disease, and full recovery of peripheral blood counts: Platelets ≥100×10\^9/L, and absolute neutrophil count (ANC) ≥1.0×10\^9/L), or CRh \[satisfaction of all criteria for CR except partial recovery of peripheral blood counts (platelets ≥ 50 ×10\^9/L and ANC ≥ 0.5×10\^9/L)\] will be analyzed.

    Time frame: Up to approximately 24 months

  35. Phase II: Duration of CR/CRh/CRi

    Duration of CR/CRh/CRi is defined as the time from the first documentation of a disease response of CR/CRh/CRi to the date of the first documented relapse event, or death due to any cause, whichever occurs first. Only participants who demonstrate a CR (defined as \< 5% blasts in the bone marrow, no circulating lymphoblasts or extramedullary disease, and full recovery of peripheral blood counts: Platelets ≥100×10\^9/L, and absolute neutrophil count (ANC) ≥1.0×10\^9/L), or CRh \[satisfaction of all criteria for CR except partial recovery of peripheral blood counts (platelets ≥ 50 ×10\^9/L and ANC ≥ 0.5×10\^9/L)\], or CRi (\<5% blasts in the bone marrow, No circulating lymphoblasts or extramedullary disease, and platelets \<100×10\^9/L and neutrophils ≥1.0×109/L or platelets ≥100 ×109/L and neutrophils \<1.0×10\^9/L) will be analyzed.

    Time frame: Up to approximately 24 months

  36. Phase II: Relapse-Free Survival (RFS)

    RFS is defined as the time from the first dose of MK-1045 to the first documented relapse, or death due to any cause (whichever occurs first). In participants who achieve CR, CRh or CRi, relapse is defined as either hematological or extramedullary relapse . Hematological relapse is defined as recurrence of blasts in the blood, or \>5% blasts in bone marrow. Extramedullary relapse is defined as recurrence of extramedullary disease after a CR.

    Time frame: Up to approximately 24 months

  37. Phase II: Overall Survival (OS)

    OS is the time from date of first study treatment to the date of death due to any reason.

    Time frame: Up to approximately 24 months

07

Study locations

8 of 11 sites recruiting
  • The Second Affiliated Hospital of Third Military Medical University ( Site 0008)
    Chongqing, Chongqing Municipality 400037, China
    Recruiting
    • Study Coordinator · Contact023-68755313
  • Southern Medical University Nanfang Hospital ( Site 0004)
    Guangzhou, Guangdong 510515, China
    Recruiting
    • Study Coordinator · Contact18665730280
  • The Second Hospital of Hebei Medical University ( Site 0003)
    Shijiazhuang, Hebei 050000, China
    Recruiting
    • Study Coordinator · Contact0311-66002778
  • The First Hospital of Harbin ( Site 0005)
    Harbin, Heilongjiang 150010, China
    Recruiting
    • Study Coordinator · Contact045184883472
  • Henan Cancer Hospital-hematology department ( Site 0002)
    Zhengzhou, Henan 450008, China
    Recruiting
    • Study Coordinator · Contact400037818
  • Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology ( Site 0010)
    Wuhan, Hubei 430022, China
    Recruiting
    • Study Coordinator · Contact02785726114
  • Tongji Hospital affiliated to Tongji Medical College of HUST ( Site 0006)
    Wuhan, Hubei 430030, China
    Recruiting
    • Study Coordinator · Contact02783662640
  • The Affiliated Hospital of Xuzhou Medical University ( Site 0007)
    Xuzhou, Jiangsu 221002, China
    Active, not recruiting

    Not enrolling at this site.

  • West China Second University Hospital, Sichuan University ( Site 0011)
    Chengdu, Sichuan 610000, China
    Completed

    Not enrolling at this site.

  • Hematology Hospital of Chinese Academy of Medical Sciences ( Site 0001)
    Tianjin, Tianjin Municipality 301617, China
    Recruiting
    • Study Coordinator · Contact022 23608030
  • The Children's Hospital of Zhejiang University School of Medicine ( Site 0009)
    Hangzhou, Zhejiang 310003, China
    Completed

    Not enrolling at this site.

08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Dec 2028, 73 months after the start.

Of 114 phase 1/2 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 56 and three quarters within 119. This study's planned 73 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2022
First posted
Oct 13, 2022
StartActual
Nov 1, 2022
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 criterion added, 1 removed
What changed in the criteria
  • RemovedHistory of clinically symptomatic metastases to the central nervous system or meninges, or other evidence of uncontrolled metastases to the CNS or meninges
  • AddedHas CNS infiltration. Participants who had previous CNS infiltration, but it was controlled with intrathecal therapy are permitted to enroll.
Oct 30, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionDose Escalation Phase: Number of Participants Who Experience a Dose-limiting Toxicity (DLT): how it is measured was reworded
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Eligibility 1 criterion added, 1 removed
    What changed in the criteria
    • RemovedHistory of clinically symptomatic metastases to the central nervous system or meninges, or other evidence of uncontrolled metastases to the CNS or meninges
    • AddedHas CNS infiltration. Participants who had previous CNS infiltration, but it was controlled with intrathecal therapy are permitted to enroll.
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionDose Escalation Phase: Number of Participants Who Experience a Dose-limiting Toxicity (DLT): how it is measured was reworded
    + 2 other changes: verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05579132
Responsible party
Sponsor
First posted
Oct 13, 2022
Start date
Nov 1, 2022
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 30, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Jianxiang Wang, Dr.
principal investigator · Institute of Hematology & Blood Diseases Hospital, China

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CD19/CD3 Bispecific Antibody MK-1045

Start the discussion